PCI Biotech Investor Relations Material
Latest events
Q4 2023 [NO]
PCI Biotech
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from PCI Biotech Holding
Access all reports
Segment Data
Access more data
R&D expenses by
Category
Clinical studies
Pre-clinical studies
Patents
CMC and equipment
Expenses by
Financials
PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of cancer through its photochemical internalization (PCI) technology platform. The company's proprietary PCI technology targets tumors by non-invasively targeting PECAM-1 receptors on tumor blood vessels using light-activated prodrugs. It has been granted patent protection in the United States, European Union, and certain other jurisdictions for certain uses of its technologies and products.
Latest articles
Daniel Ek: Co-founder and CEO of Spotify
Explore Daniel Ek's journey from a tech-savvy teenager to the co-founder and CEO of Spotify and the most influential person in the music industry.
28 Mar 2024
Companies That Had Their IPO in 1992: A Cautiously Optimistic Market
1992 marked a relatively cool IPO landscape and stock market sentiment, in the wake of the early 90s recession.
28 Mar 2024
Remembering Daniel Kahneman: Transforming Psychology and Economics
Explore Daniel Kahneman's legacy in psychology and economics, highlighting his impact on decision-making and behavioral economics.
28 Mar 2024
Ticker symbol
Country
🇳🇴 Norway